Eduthan, Neetha Paul
Donovan, Micah G.
Araya, Paula
Rachubinski, Angela L. https://orcid.org/0000-0003-1150-3976
Sullivan, Kelly D. https://orcid.org/0000-0003-2725-0205
Galbraith, Matthew D. https://orcid.org/0000-0003-0485-3927
Espinosa, Joaquin M. https://orcid.org/0000-0001-9048-1941
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI150305)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (5UL1TR002535-02S1)
Foundation for the National Institutes of Health (P30CA046934)
Global Down Syndrome Foundation
U.S. Department of Health & Human Services | NIH | National Institute on Aging (U24AG092191)
Linda Crnic Institute for Down Syndrome, Anna and John J. Sie Foundation, GI & Liver Innate Immune Program, Human Immunology and Immunotherapy Initiative, University of Colorado School of Medicine.
Linda Crnic Institute for Down Syndrome, Anna and John J. Sie Foundation, GI & Liver Innate Immune Program, Human Immunology and Immunotherapy Initiative, University of Colorado School of Medicine,
Boettcher Foundation
Article History
Received: 21 July 2025
Accepted: 28 August 2025
First Online: 24 September 2025
Competing interests
: J.M.E. has provided consulting services to Eli Lilly and Co., Gilead Sciences Inc., Biohaven Pharmaceuticals, and Perha Pharmaceuticals. All other authors declare that they have no competing interests.